J&J gives pi­o­neer­ing stem cell biotech its first Big Phar­ma deal, part­ner­ing on iP­SC CAR-T and CAR-NK

Late last sum­mer, one of the ear­li­est stem cell ther­a­py com­pa­nies got two gov­ern­ment de­ci­sions in the span of three weeks: The USP­TO grant­ed them a patent for iP­SC-de­rived CAR-T cells, and then the FDA cleared them for their first-in-hu­man CAR-NK tri­al.

Yes­ter­day, the two tech­nolo­gies land­ed them an up-to $3.1 bil­lion deal.

Fate Ther­a­peu­tics and J&J an­nounced a glob­al col­lab­o­ra­tion that will pay Fate $100 mil­lion up­front and a trove of po­ten­tial mile­stones to de­vel­op mul­ti­ple CAR-T and CAR-NK ther­a­pies. It’s the first Big Phar­ma part­ner­ship Fate has an­nounced in their 13-year ex­is­tence and the largest, al­though at least one long­time fol­low­er thought they could have land­ed more.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.